Benefits and costs of screening Ashkenazi Jewish women for BRCA1 and BRCA2

Victor R. Grann, William Whang, Judith S. Jacobson, Daniel F. Heitjan, Karen H. Antman, Alfred I. Neugut

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Purpose: To determine the survival benefit and cost-effectiveness of screening Ashkenazi Jewish women for three specific BRCA 1/2 gene mutations. Methods: We used a Markov model and Monte Carlo analysis to estimate the survival benefit and cost-effectiveness of screening for three specific mutations in a population in which their prevalence is 2.5% and the associated cancer risks are 56% for breast cancer and 16% for ovarian cancer. We assumed that the sensitivity and specificity of the test were 98% and 99%, respectively, that bilateral prophylactic oophorectomy would reduce ovarian cancer risk by 45%, and that bilateral prophylactic mastectomy would reduce breast cancer risk by 90%. We used Medicare payment data far treatment costs and Surveillance, Epidemiology, and End Results data for cancer survival. Results: Our model suggests that genetic screening of this population could prolong average nondiscounted survival by 38 days (95% probability interval, 22 to 57 days) for combined surgery, 33 days (95% probability interval, 18 to 43 days) for mastectomy 11 days (95% probability interval, 4 to 25 days) for oophorectomy, and 6 days (95% probability interval, 3 to 8 days) for surveillance. The respective cost-effectiveness ratios per life-year saved, with a discount rate of 3%, are $20,717, $29,970, $72,780, and $134,273. Conclusion: In this Ashkenazi Jewish population, with a high prevalence of BRCA1/2 mutations, genetic screening may significantly increase average survival and, depending on costs and screening/treatment strategies, may be cost-effective by the standards of accepted cancer screening tests. According to our model, screening is cost-effective only if all women who test positive undergo prophylactic surgery. These estimates require confirmation through prospective observational studies and clinical trials.

Original languageEnglish (US)
Pages (from-to)494-500
Number of pages7
JournalJournal of Clinical Oncology
Volume17
Issue number2
StatePublished - Feb 1 1999

Fingerprint

Cost-Benefit Analysis
Survival
Genetic Testing
Ovariectomy
Health Care Costs
Ovarian Neoplasms
Mutation
Breast Neoplasms
Population
Costs and Cost Analysis
Mastectomy
Medicare
Ambulatory Surgical Procedures
Early Detection of Cancer
Observational Studies
Neoplasms
Epidemiology
Clinical Trials
Prospective Studies
Sensitivity and Specificity

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Grann, V. R., Whang, W., Jacobson, J. S., Heitjan, D. F., Antman, K. H., & Neugut, A. I. (1999). Benefits and costs of screening Ashkenazi Jewish women for BRCA1 and BRCA2. Journal of Clinical Oncology, 17(2), 494-500.

Benefits and costs of screening Ashkenazi Jewish women for BRCA1 and BRCA2. / Grann, Victor R.; Whang, William; Jacobson, Judith S.; Heitjan, Daniel F.; Antman, Karen H.; Neugut, Alfred I.

In: Journal of Clinical Oncology, Vol. 17, No. 2, 01.02.1999, p. 494-500.

Research output: Contribution to journalArticle

Grann, VR, Whang, W, Jacobson, JS, Heitjan, DF, Antman, KH & Neugut, AI 1999, 'Benefits and costs of screening Ashkenazi Jewish women for BRCA1 and BRCA2', Journal of Clinical Oncology, vol. 17, no. 2, pp. 494-500.
Grann VR, Whang W, Jacobson JS, Heitjan DF, Antman KH, Neugut AI. Benefits and costs of screening Ashkenazi Jewish women for BRCA1 and BRCA2. Journal of Clinical Oncology. 1999 Feb 1;17(2):494-500.
Grann, Victor R. ; Whang, William ; Jacobson, Judith S. ; Heitjan, Daniel F. ; Antman, Karen H. ; Neugut, Alfred I. / Benefits and costs of screening Ashkenazi Jewish women for BRCA1 and BRCA2. In: Journal of Clinical Oncology. 1999 ; Vol. 17, No. 2. pp. 494-500.
@article{0f8c6d02eed748a99e2a9c1849832e9b,
title = "Benefits and costs of screening Ashkenazi Jewish women for BRCA1 and BRCA2",
abstract = "Purpose: To determine the survival benefit and cost-effectiveness of screening Ashkenazi Jewish women for three specific BRCA 1/2 gene mutations. Methods: We used a Markov model and Monte Carlo analysis to estimate the survival benefit and cost-effectiveness of screening for three specific mutations in a population in which their prevalence is 2.5{\%} and the associated cancer risks are 56{\%} for breast cancer and 16{\%} for ovarian cancer. We assumed that the sensitivity and specificity of the test were 98{\%} and 99{\%}, respectively, that bilateral prophylactic oophorectomy would reduce ovarian cancer risk by 45{\%}, and that bilateral prophylactic mastectomy would reduce breast cancer risk by 90{\%}. We used Medicare payment data far treatment costs and Surveillance, Epidemiology, and End Results data for cancer survival. Results: Our model suggests that genetic screening of this population could prolong average nondiscounted survival by 38 days (95{\%} probability interval, 22 to 57 days) for combined surgery, 33 days (95{\%} probability interval, 18 to 43 days) for mastectomy 11 days (95{\%} probability interval, 4 to 25 days) for oophorectomy, and 6 days (95{\%} probability interval, 3 to 8 days) for surveillance. The respective cost-effectiveness ratios per life-year saved, with a discount rate of 3{\%}, are $20,717, $29,970, $72,780, and $134,273. Conclusion: In this Ashkenazi Jewish population, with a high prevalence of BRCA1/2 mutations, genetic screening may significantly increase average survival and, depending on costs and screening/treatment strategies, may be cost-effective by the standards of accepted cancer screening tests. According to our model, screening is cost-effective only if all women who test positive undergo prophylactic surgery. These estimates require confirmation through prospective observational studies and clinical trials.",
author = "Grann, {Victor R.} and William Whang and Jacobson, {Judith S.} and Heitjan, {Daniel F.} and Antman, {Karen H.} and Neugut, {Alfred I.}",
year = "1999",
month = "2",
day = "1",
language = "English (US)",
volume = "17",
pages = "494--500",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "2",

}

TY - JOUR

T1 - Benefits and costs of screening Ashkenazi Jewish women for BRCA1 and BRCA2

AU - Grann, Victor R.

AU - Whang, William

AU - Jacobson, Judith S.

AU - Heitjan, Daniel F.

AU - Antman, Karen H.

AU - Neugut, Alfred I.

PY - 1999/2/1

Y1 - 1999/2/1

N2 - Purpose: To determine the survival benefit and cost-effectiveness of screening Ashkenazi Jewish women for three specific BRCA 1/2 gene mutations. Methods: We used a Markov model and Monte Carlo analysis to estimate the survival benefit and cost-effectiveness of screening for three specific mutations in a population in which their prevalence is 2.5% and the associated cancer risks are 56% for breast cancer and 16% for ovarian cancer. We assumed that the sensitivity and specificity of the test were 98% and 99%, respectively, that bilateral prophylactic oophorectomy would reduce ovarian cancer risk by 45%, and that bilateral prophylactic mastectomy would reduce breast cancer risk by 90%. We used Medicare payment data far treatment costs and Surveillance, Epidemiology, and End Results data for cancer survival. Results: Our model suggests that genetic screening of this population could prolong average nondiscounted survival by 38 days (95% probability interval, 22 to 57 days) for combined surgery, 33 days (95% probability interval, 18 to 43 days) for mastectomy 11 days (95% probability interval, 4 to 25 days) for oophorectomy, and 6 days (95% probability interval, 3 to 8 days) for surveillance. The respective cost-effectiveness ratios per life-year saved, with a discount rate of 3%, are $20,717, $29,970, $72,780, and $134,273. Conclusion: In this Ashkenazi Jewish population, with a high prevalence of BRCA1/2 mutations, genetic screening may significantly increase average survival and, depending on costs and screening/treatment strategies, may be cost-effective by the standards of accepted cancer screening tests. According to our model, screening is cost-effective only if all women who test positive undergo prophylactic surgery. These estimates require confirmation through prospective observational studies and clinical trials.

AB - Purpose: To determine the survival benefit and cost-effectiveness of screening Ashkenazi Jewish women for three specific BRCA 1/2 gene mutations. Methods: We used a Markov model and Monte Carlo analysis to estimate the survival benefit and cost-effectiveness of screening for three specific mutations in a population in which their prevalence is 2.5% and the associated cancer risks are 56% for breast cancer and 16% for ovarian cancer. We assumed that the sensitivity and specificity of the test were 98% and 99%, respectively, that bilateral prophylactic oophorectomy would reduce ovarian cancer risk by 45%, and that bilateral prophylactic mastectomy would reduce breast cancer risk by 90%. We used Medicare payment data far treatment costs and Surveillance, Epidemiology, and End Results data for cancer survival. Results: Our model suggests that genetic screening of this population could prolong average nondiscounted survival by 38 days (95% probability interval, 22 to 57 days) for combined surgery, 33 days (95% probability interval, 18 to 43 days) for mastectomy 11 days (95% probability interval, 4 to 25 days) for oophorectomy, and 6 days (95% probability interval, 3 to 8 days) for surveillance. The respective cost-effectiveness ratios per life-year saved, with a discount rate of 3%, are $20,717, $29,970, $72,780, and $134,273. Conclusion: In this Ashkenazi Jewish population, with a high prevalence of BRCA1/2 mutations, genetic screening may significantly increase average survival and, depending on costs and screening/treatment strategies, may be cost-effective by the standards of accepted cancer screening tests. According to our model, screening is cost-effective only if all women who test positive undergo prophylactic surgery. These estimates require confirmation through prospective observational studies and clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=0033015788&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033015788&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 494

EP - 500

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 2

ER -